Whether Corcept Therapeutics represents a good stock to buy depends on an individual investor's risk tolerance and growth strategy regarding biotechnology equities. Growth-oriented investors frequently highlight its strong commercial profitability, zero debt, robust cash reserves, and expanding addressable markets in endocrinology and oncology as compelling reasons to establish long-term positions.